Mustafa Khasraw

Overview:

I am a medical oncologist, neuro-oncologist, tenured professor of medicine and neurooncology, and Deputy Director of the Center for Cancer Immunotherapy, Duke Cancer Institute, where we are tasked to speed up clinical research and translation for scientists across all departments and all tumor types at Duke, who have made discoveries that show promise for developing new immunotherapies.

I am leading several clinical and translational programs with significant laboratory collaborations with an interest in innovative trials designed to improve the outcome of patients with cancers of the CNS. In addition, I am the principal investigator of first in human, phase I, II, and window of opportunity trials in CNS malignancies and solid tumors. 

I serve as an advisor and grant reviewer for several non-profits and patient advocacy groups. I am a Fellow of the Royal Australasian College of Physicians and an Elected Fellow of the Royal College of Physicians (UK). 

Positions:

Professor of Neurosurgery

Neurosurgery
School of Medicine

Professor in Medicine

Medicine, Medical Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 2001

Rijksuniversiteit Groningen (The Netherlands)

Grants:

Astellas 1951-CL-0101

Administered By
Duke Cancer Institute
Awarded By
Astellas Pharma Global Development, Inc
Role
Principal Investigator
Start Date
End Date

Celldex CDX-527

Administered By
Duke Cancer Institute
Awarded By
Celldex Therapeutics, Inc.
Role
Principal Investigator
Start Date
End Date

A Multicenter, Open-Label Study with a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients with Recurrent Glioblastoma Multiform (WHO Grade IV) After Failure of Standard First Line

Administered By
Duke Cancer Institute
Awarded By
CNS Pharmaceuticals, Inc
Role
Principal Investigator
Start Date
End Date

Phase 1 BNT152+153 in patients with solid tumors

Administered By
Duke Cancer Institute
Awarded By
BioNTech SE
Role
Principal Investigator
Start Date
End Date

PARAMETer: A window of opportunity study of Patritumab Deruxtecan in patients with brain metastases

Administered By
Duke Cancer Institute
Awarded By
Daiichi Sankyo Inc
Role
Principal Investigator
Start Date
End Date

Publications:

Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australi

AIM: Palbociclib was approved in the United States in 2015 to treat estrogen receptor-positive/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC). This study evaluated outcomes and safety in patients treated with palbociclib in Australia and India with hormone receptor-positive (HR+)/HER2- ABC before palbociclib became commercially available. METHODS: Postmenopausal women (≥18 years) with HR+/HER2- ABC who were appropriate candidates for letrozole therapy received palbociclib 125 mg once daily for 21 days followed by 7 days off, and letrozole 2.5 mg once daily (continuous). Safety, tumor response, and patient-reported outcomes (Australian cohort) were evaluated. RESULTS: In total, 252 patients received palbociclib plus letrozole (Australia, n = 152; India, n = 100). More patients in the Australian versus Indian cohort had received prior chemotherapy (advanced/metastatic setting: 45.9% vs. 32.0%), endocrine therapy (advanced/metastatic setting: 63.2% vs. 54.3%), and advanced/metastatic therapies (61.8% vs. 31.0%). The most frequently reported all-grade palbociclib-related treatment-emergent adverse events were neutropenia (66.7%), fatigue (35.3%), and stomatitis (26.6%); grade 3/4 neutropenia was reported as palbociclib-related in 62.7% of patients. Febrile neutropenia was reported in six patients (2.4%). Eight patients (3.2%) discontinued because of an adverse event. The objective response rate was 19.4% (95% CI, 14.7%-24.9%) overall and 2.3% in Australian patients with ≥2 lines of prior therapy for metastatic disease. Patient-reported quality of life scores were maintained throughout the study. CONCLUSIONS: In an expanded access setting in Australia and India, palbociclib plus letrozole was well tolerated in patients with HR+/HER2- ABC, with a safety profile consistent with previous reports.
Authors
Loi, S; Karapetis, CS; McCarthy, N; Oakman, C; Redfern, A; White, M; Khasraw, M; Doval, DC; Gore, V; Alam, M; Binko, J; Lu, DR; Kim, S; Boyle, F
URI
https://scholars.duke.edu/individual/pub1504044
PMID
34908235
Source
pubmed
Published In
Asia Pac J Clin Oncol
Published Date
DOI
10.1111/ajco.13653

LOW AND INTERMEDIATE GRADE GLIOMA UMBRELLA STUDY OF MOLECULAR GUIDED THERAPIES (LUMOS) STUDY

Authors
Kong, B; Sim, H-W; Amanuel, B; Day, B; Buckland, M; Verhaak, R; Yip, S; Johns, T; Lwin, Z; Rosenthal, M; Nowak, AK; Barnes, EH; Scott, AM; Parkinson, J; Jeffree, R; Lourenco, RDA; Lau, P; Whittle, J; Hovey, E; Cher, L; Kichendasse, G; Hall, M; Robinson, C; Thomas, M; Giardina, T; Tu, E; Khasraw, M; Koh, E-S; Gan, H
MLA Citation
Kong, Benjamin, et al. “LOW AND INTERMEDIATE GRADE GLIOMA UMBRELLA STUDY OF MOLECULAR GUIDED THERAPIES (LUMOS) STUDY.” Neuro Oncology, vol. 23, 2021, pp. 106–106.
URI
https://scholars.duke.edu/individual/pub1511958
Source
wos-lite
Published In
Neuro Oncology
Volume
23
Published Date
Start Page
106
End Page
106

Highlights from the Literature

Authors
Soffietti, R; Khasraw, M; Huse, J; Hegi, M
MLA Citation
Soffietti, R., et al. “Highlights from the Literature.” Neuro Oncology, vol. 23, no. 1, Jan. 2021, pp. 14–16. Scopus, doi:10.1093/neuonc/noaa271.
URI
https://scholars.duke.edu/individual/pub1505243
Source
scopus
Published In
Neuro Oncology
Volume
23
Published Date
Start Page
14
End Page
16
DOI
10.1093/neuonc/noaa271

Glioma progression is shaped by genetic evolution and microenvironment interactions.

The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treatment-associated cellular and genetic changes, we analyzed RNA and/or DNA sequencing data from the temporally separated tumor pairs of 304 adult patients with isocitrate dehydrogenase (IDH)-wild-type and IDH-mutant glioma. Tumors recurred in distinct manners that were dependent on IDH mutation status and attributable to changes in histological feature composition, somatic alterations, and microenvironment interactions. Hypermutation and acquired CDKN2A deletions were associated with an increase in proliferating neoplastic cells at recurrence in both glioma subtypes, reflecting active tumor growth. IDH-wild-type tumors were more invasive at recurrence, and their neoplastic cells exhibited increased expression of neuronal signaling programs that reflected a possible role for neuronal interactions in promoting glioma progression. Mesenchymal transition was associated with the presence of a myeloid cell state defined by specific ligand-receptor interactions with neoplastic cells. Collectively, these recurrence-associated phenotypes represent potential targets to alter disease progression.
Authors
Varn, FS; Johnson, KC; Martinek, J; Huse, JT; Nasrallah, MP; Wesseling, P; Cooper, LAD; Malta, TM; Wade, TE; Sabedot, TS; Brat, D; Gould, PV; Wöehrer, A; Aldape, K; Ismail, A; Sivajothi, SK; Barthel, FP; Kim, H; Kocakavuk, E; Ahmed, N; White, K; Datta, I; Moon, H-E; Pollock, S; Goldfarb, C; Lee, G-H; Garofano, L; Anderson, KJ; Nehar-Belaid, D; Barnholtz-Sloan, JS; Bakas, S; Byrne, AT; D'Angelo, F; Gan, HK; Khasraw, M; Migliozzi, S; Ormond, DR; Paek, SH; Van Meir, EG; Walenkamp, AME; Watts, C; Weiss, T; Weller, M; Palucka, K; Stead, LF; Poisson, LM; Noushmehr, H; Iavarone, A; Verhaak, RGW; GLASS Consortium,
MLA Citation
Varn, Frederick S., et al. “Glioma progression is shaped by genetic evolution and microenvironment interactions.Cell, vol. 185, no. 12, June 2022, pp. 2184-2199.e16. Pubmed, doi:10.1016/j.cell.2022.04.038.
URI
https://scholars.duke.edu/individual/pub1524366
PMID
35649412
Source
pubmed
Published In
Cell
Volume
185
Published Date
Start Page
2184
End Page
2199.e16
DOI
10.1016/j.cell.2022.04.038

COMPARING KNOWLEDGE OF AND BELIEFS ABOUT PALLIATIVE CARE AMONG NEURO-ONCOLOGY PATIENTS, CAREGIVERS, PROVIDERS AND A NATIONALLY-REPRESENTATIVE US SAMPLE

Authors
Johnson, M; Khasraw, M; Kim, J-Y; Cort, N; Herndon, J; Ramirez, L; Lipp, E; Landi, D; Desjardins, A; Friedman, H; Ashley, DM; Affronti, M; Casarett, DJ; Peters, KB
URI
https://scholars.duke.edu/individual/pub1511959
Source
wos-lite
Published In
Neuro Oncology
Volume
23
Published Date
Start Page
189
End Page
189

Research Areas:

Anti-cancer
Cancer
Cancer Therapy Resistance
Cancer Vaccines
Cancer genes
Cancer--Immunotherapy
Drug development
Immunotherapy